… About ProQR Therapeutics An innovative biotech company advancing … Axiomer RNA-editing platform technology. We are ProQR We are ProQR We are ProQR, a biotechnology company dedicated to …
… ProQR founding story When our CEO, Daniel A. de Boer, knew … his newborn son had an incurable rare disease, he founded ProQR to help people like his son. Learn more. A personal … a difference in the world. Daniel continues to motivate ProQRians to remind them of the company’s mission and to …
… ProQR corporate presentation Download the latest ProQR corporate presentation (PDF). Creating medicines for patients in need ProQR corporate presentation (PDF) Internal link Download …
ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
… Building an Inclusive ProQR At ProQR we strive to create an inclusive culture where everyone … logo to incorporate the pride rainbow flag. Pride month at ProQR is an opportunity to celebrate and thank all of the …
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
In June we caught up with our Lead Talent Acquisition, Silvia Catellani, to talk about ProQR, Pride, and driving an inclusive culture for present and future ProQRians.
